Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Tiago Reis Marques, Mathew Lazarus, Joy Cannon, Ildefonso Ismael Rodriguez Rivera
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4410822643